Drug Profile


Alternative Names: LF 160687; LF16-0687MS; XY-2405

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Fournier Pharma
  • Developer Fournier Pharma; London School of Hygiene & Tropical Medicine
  • Class Analgesics; Anti-inflammatories; Quinolines; Small molecules
  • Mechanism of Action Bradykinin B2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries

Highest Development Phases

  • Discontinued Brain injuries

Most Recent Events

  • 15 Mar 2007 Xytis initiates enrolment in the BRAIN trial for traumatic brain injury
  • 11 Jan 2007 Phase-II clinical trials in Head injuries in South Africa (SC)
  • 11 Jan 2007 Phase-II clinical trials in Head injuries in United Kingdom (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top